Proteome-wide Mendelian randomization and therapeutic targets for bladder cancer
Abstract Objective To identify therapeutic protein targets for bladder cancer (BCa) using Mendelian randomization (MR) and assess potential adverse effects of these targets. Methods A proteome-wide MR study was conducted to determine causal relationships between plasma proteins and BCa risk. In the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12894-024-01677-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846112133793710080 |
|---|---|
| author | Meng-Hua Wu Min-Heng Zhang Xiao-Dong Hu Hai-Xia Fan |
| author_facet | Meng-Hua Wu Min-Heng Zhang Xiao-Dong Hu Hai-Xia Fan |
| author_sort | Meng-Hua Wu |
| collection | DOAJ |
| description | Abstract Objective To identify therapeutic protein targets for bladder cancer (BCa) using Mendelian randomization (MR) and assess potential adverse effects of these targets. Methods A proteome-wide MR study was conducted to determine causal relationships between plasma proteins and BCa risk. In the discovery stage, the plasma proteins (Exposure) were sourced from the R10 of Finnish database, Olink (619 samples across 2925 proteins) and SomaScan (828 samples across 7596 proteins), and Iceland database. In the replication stage, plasma proteins (Exposure) were sourced from the UK-Biobank-PPP database (54,219 participants and 2940 proteins). Summary-level data for BCa (Outcome) were obtained from the UK Biobank (UKB-SAIGE: cancer of bladder) in the discovery phase and the FinnGen consortium (FinnGen R11: cancer of bladder) in the replication phase. Colocalization and fix-effect meta-analyses were performed to validate MR findings. Finally, phenome-wide association study (Phe-WAS) was conducted to explore the side effects of druggable proteins utilizing UKB-SAIGE encompassing 783 phenotypes. Results The MR analysis identified PSCA, LY6D, and SLURP1 as proteins with a genetic association to BCa risk. SLURP1 was confirmed in the replication phase, with a meta-analysis showing an odds ratio of 1.50 (95% CI: 1.30–1.74, P < 0.001). Phe-WAS indicated potential side effects for these targets. Conclusion This study provides insights into the causal relationships of plasma proteins with BCa, identifying PSCA, LY6D, and SLURP1 as potential therapeutic targets, with implications for future BCa treatment strategies. |
| format | Article |
| id | doaj-art-a3b024d5dd744c9282db592b13596aa4 |
| institution | Kabale University |
| issn | 1471-2490 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj-art-a3b024d5dd744c9282db592b13596aa42024-12-22T12:50:18ZengBMCBMC Urology1471-24902024-12-0124111010.1186/s12894-024-01677-4Proteome-wide Mendelian randomization and therapeutic targets for bladder cancerMeng-Hua Wu0Min-Heng Zhang1Xiao-Dong Hu2Hai-Xia Fan3Department of Urology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical UniversityDepartment of Gerontology, the First People’s Hospital of JinzhongFirst Hospital of Shanxi Medical UniversityFirst Hospital of Shanxi Medical UniversityAbstract Objective To identify therapeutic protein targets for bladder cancer (BCa) using Mendelian randomization (MR) and assess potential adverse effects of these targets. Methods A proteome-wide MR study was conducted to determine causal relationships between plasma proteins and BCa risk. In the discovery stage, the plasma proteins (Exposure) were sourced from the R10 of Finnish database, Olink (619 samples across 2925 proteins) and SomaScan (828 samples across 7596 proteins), and Iceland database. In the replication stage, plasma proteins (Exposure) were sourced from the UK-Biobank-PPP database (54,219 participants and 2940 proteins). Summary-level data for BCa (Outcome) were obtained from the UK Biobank (UKB-SAIGE: cancer of bladder) in the discovery phase and the FinnGen consortium (FinnGen R11: cancer of bladder) in the replication phase. Colocalization and fix-effect meta-analyses were performed to validate MR findings. Finally, phenome-wide association study (Phe-WAS) was conducted to explore the side effects of druggable proteins utilizing UKB-SAIGE encompassing 783 phenotypes. Results The MR analysis identified PSCA, LY6D, and SLURP1 as proteins with a genetic association to BCa risk. SLURP1 was confirmed in the replication phase, with a meta-analysis showing an odds ratio of 1.50 (95% CI: 1.30–1.74, P < 0.001). Phe-WAS indicated potential side effects for these targets. Conclusion This study provides insights into the causal relationships of plasma proteins with BCa, identifying PSCA, LY6D, and SLURP1 as potential therapeutic targets, with implications for future BCa treatment strategies.https://doi.org/10.1186/s12894-024-01677-4Plasma proteinsMendelian randomizationBladder cancerDrug targetMeta-analysisPhenome wide association study |
| spellingShingle | Meng-Hua Wu Min-Heng Zhang Xiao-Dong Hu Hai-Xia Fan Proteome-wide Mendelian randomization and therapeutic targets for bladder cancer BMC Urology Plasma proteins Mendelian randomization Bladder cancer Drug target Meta-analysis Phenome wide association study |
| title | Proteome-wide Mendelian randomization and therapeutic targets for bladder cancer |
| title_full | Proteome-wide Mendelian randomization and therapeutic targets for bladder cancer |
| title_fullStr | Proteome-wide Mendelian randomization and therapeutic targets for bladder cancer |
| title_full_unstemmed | Proteome-wide Mendelian randomization and therapeutic targets for bladder cancer |
| title_short | Proteome-wide Mendelian randomization and therapeutic targets for bladder cancer |
| title_sort | proteome wide mendelian randomization and therapeutic targets for bladder cancer |
| topic | Plasma proteins Mendelian randomization Bladder cancer Drug target Meta-analysis Phenome wide association study |
| url | https://doi.org/10.1186/s12894-024-01677-4 |
| work_keys_str_mv | AT menghuawu proteomewidemendelianrandomizationandtherapeutictargetsforbladdercancer AT minhengzhang proteomewidemendelianrandomizationandtherapeutictargetsforbladdercancer AT xiaodonghu proteomewidemendelianrandomizationandtherapeutictargetsforbladdercancer AT haixiafan proteomewidemendelianrandomizationandtherapeutictargetsforbladdercancer |